DiaCarta SARS-CoV-2 Test Kit Receives CE Mark

Mar 23, 2020 | staff reporter

NEW YORK – Molecular diagnostic firm DiaCarta said on Monday that its QuantiVirus SARS-CoV-2 test recently received the CE mark. The firm has also filed for Emergency Use Authorization of the test with the US Food and Drug Administration.

The company's qRT-PCR test detects viral RNA extracted from nasopharyngeal swabs, oropharyngeal swabs, and sputum. it targets three genes of SARS-CoV-2: the N, Orf1ab, and E genes.

The test, which was clinically validated in the company's CLIA-certified lab in Richmond, California, has 96 percent sensitivity and 100 percent specificity, according to DiaCarta, and doesn't cross-react with other types of coronaviruses.

Filed under

Molecular Diagnostics

PCR

Infectious Disease

FDA

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.

Neurological Outcomes Linked to Innate Immune Features After Cardiac Arrest

Researchers reporting in Med dig into immune features found a few hours after cardiac arrest that correspond with neurological outcomes.

Mouse Study Finds Circadian Rhythm-Related Gene Expression Changes Linked to Sleep Apnea

A paper in PLOS Biology reveals tissue-specific circadian rhythm and gene expression patterns in an intermittent hypoxia-based mouse model of obstructive sleep apnea.

Polygenic Risk Score to Predict Preeclampsia, Gestational Hypertension in Pregnant Women

Researchers in Nature Medicine provide new mechanistic insights into the development of hypertensive disorders of pregnancy, which may help develop therapeutics.